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Abstract
Background: Psychostimulants (methylphenidate and amphetamines) are considered first-line therapy for attention-deficit/hyperactivity disorder (ADHD). 
Lisdexamfetamine dimesylate (LDX) is a new psychostimulant approved for the treatment of ADHD in Brazil. The pharmacologically active fraction, d-amphet-
amine, is gradually released by hydrolysis of the LDX prodrug. Objectives: To perform a systematic review of the literature of the efficacy and safety of LDX 
in the treatment of ADHD in children and adolescents. Methods: Medline/PubMed searches for “d-amfetamine”, “lisdexamfetamine” and “lisdexamfetamine 
dimesylate” were conducted including articles available from January 2000 to November 2013. Additional references were identified using references listed 
in those articles. Further data on LDX were requested from its manufacturer. Results: Thirty-one papers were found related to ADHD treatment in children 
and adolescents. Discussion: The therapeutic benefits of LDX in children with ADHD are achieved as early as 1.5 hours after its administration and last for up 
to 13 hours, with efficacy comparable or superior to that of other available psychostimulants. The literature also reports efficacy in long-term treatment, with 
safety and tolerability profiles comparable to those of other stimulants used for the treatment of ADHD. Most of the adverse events associated with LDX are 
considered to be mild or moderate in severity, with the most common being loss of appetite and insomnia. 
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Resumo
Contexto: Psicoestimulantes (metilfenidato e anfetaminas) são considerados como tratamento farmacológico de primeira linha no tratamento do transtorno 
do déficit de atenção e hiperatividade (TDAH). O dimesilato de anfetamina é um novo psicoestimulante aprovado para uso no Brasil, cuja fração farma-
cologicamente ativa, a d-anfetamina, é gradualmente liberada por hidrólise da pró-droga. Objetivos: Realizar uma revisão sistemática de literatura sobre 
eficácia e segurança da LDX no tratamento de TDAH de crianças e adolescentes. Métodos: Busca na base Medline/PubMed com os termos “d-amfetamine”, 
“lisdexamfetamine” e “lisdexamfetamine dimesilate”, de janeiro de 2000 até novembro de 2013. Referências adicionais foram retiradas das referências dos 
artigos obtidos; dados também foram obtidos do fabricante. Resultados: Trinta e um artigos foram encontrados, relacionados ao tratamento de TDAH em 
crianças e adolescentes. Conclusões: Os benefícios terapêuticos da LDX são obtidos em até 1,5 hora após administração e se estendem até 13 horas, com 
eficácia comparável ou superior à dos demais psicoestimulantes disponíveis. A literatura também documenta eficácia em longo prazo, com perfis de segurança 
e tolerabilidade comparáveis aos dos demais estimulantes usados no tratamento do TDAH. A maioria dos eventos adversos associados à LDX é considerada 
leve ou moderada quanto à gravidade, sendo os eventos mais comuns perda de apetite e insônia.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is characterized by 
inattention, hyperactivity and impulsiveness at levels higher than 
expected for age. ADHD has been described in various cultures 
and societies as the most common neurobehavioral disorder in 
children1, and is associated with poor performance in family, social 
and academic contexts, especially when not diagnosed and treated 
effectively2-5. The most widely documented negative effects of 
ADHD include poor school performance in children and adolescents. 
For example, even considering family income and the parents’ level 
of education as significant variables in academic performance (an 
aspect especially important in countries such as Brazil), ADHD is 
associated with poorer academic performance6. 
The prevalence of ADHD worldwide in children under 18 years 
old is estimated at 5.3%, with greater frequency of recognition in 
children than in adolescents, and in boys than in girls7. In studies 
in Brazil, the estimates of ADHD prevalence in children and 
adolescents range from 5.8% to 19.9%, and vary depending on 
the diagnostic criteria used and the type of sample analyzed8-11. 
ADHD often persists beyond adolescence into adulthood, although 
the presentation of symptoms differs between adults, children, and 
adolescents12. 
Despite the extensive scientific literature and dozens of 
associations formed by people with ADHD and family members 
throughout the world, there are still substantial misconceptions about 
the nature of ADHD and its treatment. In a survey conducted in Brazil 
of representative groups of physicians, psychologists, teachers and 
the general public, each of these groups reported beliefs that were 
not based on scientific evidence13. For example, among physicians, 
more than 50% of pediatricians and neurologists expressed the belief 
that ADHD was the result of absent parents. In addition, more than 
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50% of the psychologists expressed the belief that ADHD can be 
treated with psychotherapy alone.
Treatment strategies for ADHD include counseling, 
psychoeducation, psychotherapy, and pharmacological treatment. 
Behavioral parent training, behavior management in the classroom 
and behavior interventions in various contexts are considered to 
be effective in managing ADHD14. Pharmacological therapy is an 
important part of management of ADHD, with psychostimulants 
considered first line therapy15.  
Psychostimulants are considered the most effective of all the 
medications used to treat ADHD16, and are available in immediate- 
and prolonged-release formulations. Potential limitations of 
the use of immediate-release formulations include the need for 
frequent doses that potentially reduce adherence, and fluctuations 
in serum levels which have been associated with adverse events. 
Although there is some evidence for this, it is not yet clear whether 
immediate-release psychostimulants produce greater abuse potential 
than prolonged-release formulations17. Among the prolonged 
action psychostimulants used in treating ADHD, there are various 
formulations of methylphenidate and amphetamine (with differing 
means of release and half-lives). A recent Cochrane review 
demonstrated the efficacy of amphetamines in treating this disorder18. 
Lisdexamfetamine dimesylate (LDX) is the newest drug in this 
class, having been developed as a prodrug of dextroamphetamine 
(d-amphetamine) aimed at providing long-acting treatment effects 
and a reduced risk of abuse19. The purpose of this article is to review 
the pharmacokinetics, efficacy and safety of LDX in treating ADHD 
in children and adolescents.
Methods
Medline/PubMed searches for lisdexamfetamine were conducted 
including articles available form January 2000 to November 2014. 
Additional references were identified using the reference lists 
of those articles. Further data on LDX were requested from its 
manufacturer. The articles included were selected based on the 
author’s decision of their relevance to the topic.
Results
Forty-one papers were found related to ADHD treatment with 
lisdexamfetamine in children and adolescents with ADHD. They 
were sorted by topics, as indicated below.
Pharmacokinetics
LDX is administered orally as an inactive parent compound that 
is rapidly and almost completely absorbed in the gastrointestinal 
tract. LDX is subsequently metabolized by enzyme hydrolysis into 
l-lysine (an essential amino acid) and d-amphetamine, the active 
component17,20 (Figure 1). The hydrolysis of the inactive component 
to the active drug is a relatively slow process that occurs mainly in 
the blood19-21. It has been suggested that this relatively slow stage 
contributes to the long-lasting effect and possibly also to reduced 
“drug craving”, an aspect considered critical in the development of 
abuse after both oral and intravenous administration19,22.
In children 6-12 years of age, the time to maximum blood 
concentration (Tmax) of d-amphetamine after the administration of 
a single dose of LDX (30, 50 or 70 mg) was 3.4-3.6 hours and the 
half-life was 8.6-8.9 hours, with no significant differences among 
the various doses21. These parameters are similar to those of the 
immediate-release formulations of mixed-salt psychostimulants, 
but shorter than the Tmax of prolonged-release formulations such 
as Adderall XR (Shire U.S., Inc., East Hanover, NJ, U.S.; Tmax = 
7 hours). Systemic exposure to d-amphetamine showed that the 
maximum blood concentration (Cmax), area under the curve (AUC) 
from time zero to infinity (AUC
0-∞
) and AUC from time zero to the 
last measurable concentration (AUC
0
-t) was proportional to the dose, 
with low interpatient variation. Furthermore, in another study that 
measured Cmax, Tmax and AUC in children 6-12 years of age with 
ADHD, the interpatient variability (as measured by the coefficient 
of variation) for these parameters was lower for d-amphetamine 
following administration of a 70 mg dose of LDX than following 
the administration of 30 mg of extended-release mixed amphetamine 
salts23. This suggests that the concentrations of the active metabolite 
are proportional to the dose of LDX, with low variation among 
individuals21,24. 
Some controlled-release formulations of psychostimulants are 
sensitive to alterations in gastric pH (e.g., due to the concomitant 
presence of antacids or proton pump inhibitors) or gastrointestinal 
transit time, potentially leading to pharmacokinetic variability25. 
Significant variations in the plasma levels of d-amphetamines were 
reported when one compared their administration with and without 
food intake (Adderall XR)26,27. It has been demonstrated in vitro that 
the solubility of LDX is not affected by pH within a physiologically 
relevant range (pH = 1-8), and is slightly reduced when the pH is 
substantially increased (pH = 8-13)20. Given that LDX is a prodrug 
and not dependent on a controlled-release mechanism, the changes in 
gastrointestinal transit should not alter its effects20. Furthermore, food 
does not significantly or clinically affect the bioavailability of LDX28. 
The administration of a single dose of LDX after a high-fat meal 
compared with a fasting state resulted in a delay of approximately 1 
hour in d-amphetamine Tmax, although the Cmax and AUC were similar
28.
LDX has demonstrable efficacy 2 hours after administration that 
is maintained up to 12 hours23. Another study reported beneficial 
effects of LDX lasting from 1.5 to 13 hours post-dose29. In a 4-week, 
double-blind, randomized study in children, the evening rebound 
associated with LDX proved to be less than with placebo (2.9% 
vs 9.7%, respectively)30. Such aspects are potentially relevant for 
clinical practice due to the need for symptomatic control during 
various activities throughout the day23. In addition, the consistent 
plasma concentrations of the drug prevented fluctuations and the 
associated rebound effects. Furthermore, the absence of fluctuations 
Figure 1. Enzymatic activation of the prodrug (lisdexamfetamine dimesylate) for the active compound of d-amphetamine. 
d-amphetamine
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in plasma concentrations (peaks and troughs) throughout the day 
minimized or eliminated the “sudden-onset” or “peak” effects 
potentially related to abuse31. In a study of potential abuse of LDX 
comparing intranasal administration with oral administration, 
similar values were found for Cmax, Tmax, AUC and half-life in both 
groups, indicating that intranasal dosing does not cause accelerated 
absorption32.  
Efficacy
LDX has been approved in the U.S., Canada, Australia, several 
European countries and Brazil; in Brazil it has been approved for 
the treatment of children, adolescents and adults.
The first Phase II, randomized, cross-over study, with controls 
(placebo and active control), compared LDX (30, 50 or 70 mg) with 
placebo in 52 school-age children in a laboratory classroom setting23. 
Extended-release mixed amphetamine salts (10, 20 or 30 mg) were 
included as a reference arm during the study. Patients 6-12 years 
of age were initially treated with amphetamine salts for 3 weeks, 
followed by a double-blind crossover period during which they were 
given LDX, mixed amphetamine salts and placebo for 1 week each in 
a randomized order. Both active treatments were superior to placebo, 
using the Swanson, Kotkin, Agler, M-Flynn and Pelham Deportment 
Scale (SKAMP-DS)23. Significant improvements were also observed 
in the Clinical Global Impressions-Improvement (CGI-I) Scale, 
with 74% of patients receiving LDX classified as improved, 72% of 
those receiving mixed amphetamine salts and 18% of patients in the 
placebo group. In these evaluations, a greater percentage of children 
were considered to have been “very much improved” with LDX 
(32%) compared with mixed amphetamine salts (16%)23.
The second study was a Phase III, multi-center, placebo-
controlled, forced-dose study in 290 children who received LDX 
30, 50 or 70 mg33. Efficacy was observed after the first week of 
treatment, at which time the reductions in the ADHD Rating Scale 
IV (ADHD-RS-IV) scores were significantly greater for patients 
treated with LDX than among those receiving placebo. At the end 
of 4 weeks, significant reductions in the ADHD-RS-IV scale, CGI 
scale scores and Conners’ Parents Rating Scale (CPRS) were found 
for each dose of LDX compared with placebo (all with P < 0.01). 
The reductions in total ADHD-RS-IV scores were approximately 4 
to 5 times greater with the active treatment than with placebo, with 
the greatest decreases observed for the 70 mg LDX dose33.
Subsequent studies have investigated the use of LDX in long-
term ADHD treatment. In a laboratory classroom study in 117 
school-children, LDX provided therapeutic efficacy in as little as 
1.5 hours after administration and the effects were maintained for up 
to 13 hours post-dose (last time point evaluated)29. Compared with 
placebo, significantly greater efficacy (P < 0.005) was found in the 
SKAMP and Permanent Product Measure of Performance scores with 
LDX at 1.5 and 13 hours post-dose29. The long-term efficacy of LDX 
was demonstrated in an 11-month open-label study involving 272 
children34. Following dose-titration over the first 4 weeks, children 
6-12 years of age were given 30, 50 or 70 mg doses of LDX per day 
for a maintenance period of 11 months. Efficacy (evaluated using 
the ADHD-RS and CGI scales) was pronounced, improved over 
the first 4 weeks, and was sustained throughout the study follow-up 
period. At the end of the study, there was a significant improvement 
in mean ADHD-RS scores (P < 0.0001), representing a change from 
baseline of more than 60%34. 
In a 4-week, double-blind study with forced titration involving 
314 adolescents (13-17 years of age) with ADHD, LDX treatment 
resulted in significant reductions in ADHD symptoms35. At the end 
of the study, the mean change in the total ADHD-RS-IV scores was 
significantly greater than placebo for all doses (30, 50 and 70 mg, 
P ≤ 0.0056). In addition, differences in total scores for all LDX doses 
were significant at all weeks of the study compared with placebo. At 
the end of the study, 69.1% of patients treated with LDX were rated 
as very much/much improved based on CGI-I scores compared with 
39.5% of patients receiving placebo (P < 0.0001)35.
One of the key aspects of the treatment of ADHD is the need to 
control symptoms at different times during the day, something that 
could be problematic when using short-acting formulations. A recent 
study evaluating behavioral aspects using objective measures in the 
form of Conners’ Parent Rating Scale-Revised (CPRS-R) in 336 
children and adolescents throughout the day showed that there was 
a consistent benefit in the four subscales with a single, optimized 
dose of LDX (30, 50 or 70 mg)36.
Only one head-to-head study has directly compared LDX with 
another ADHD medication. This study was conducted in 267 children 
and adolescents, comparing LDX (in doses of 30, 50 or 70 mg) and 
atomoxetine (0.5 to 1.2 mg/kg) over 9 weeks37. LDX was associated 
with a significantly more rapid and robust treatment response than 
atomoxetine.
A recent phase III study in children and adolescents (6 to 17 
years) with ADHD from 10 European countries included long-acting, 
osmotic-release oral system methylphenidate (OROS-MPH) as an 
active reference arm to provide validation of the study design38. 
Although not designed to support a formal statistical comparison 
of LDX and OROS-MPH, a post hoc analysis suggested a greater 
effect of LDX than OROS-MPH when assessed using the ADHD-
RS-IV (effect sizes 1.80 and 1.26, respectively) and CGI-I39. This 
finding appears to support a Cochrane review which demonstrated 
the efficacy of amphetamines in the treatment of ADHD in adults18, 
something demonstrated for LDX in recent studies in adults40. 
Although there are no data on efficacy for the symptoms of 
depression and anxiety in children and adolescents with ADHD, a 
post hoc analysis41 of an open-label study over 7 weeks with LDX 
in children, evaluating the Behavior Rating Inventory of Executive 
Function (BRIEF) emotional control domain, revealed significant 
improvements associated with LDX treatment (P < 0.0001) in 
addition to improvements in the symptoms of ADHD.
Studies of pharmacological treatments for ADHD frequently 
use quality of life (QoL) and functional impairment indicators, 
aspects that are related but not necessarily proportional to the 
cardinal symptoms of ADHD. A 7-week, double-blind, placebo- 
and active-controlled study of LDX42 utilised the Child Health and 
Illness Profile-Child Edition: Parent Report Form (CHIP-CE: PRF) 
and the Weiss Functional Impairment Rating Scale-Parent Report 
(WFIRS-P) questionnaires. This study found that both LDX and 
the active reference treatment, OROS-MPH, were associated with 
improvements in QoL and functioning, indicating treatment benefits 
beyond an improvement in the primary symptoms of ADHD.
Safety
Since LDX is a prodrug of d-amphetamine, one expects a tolerability 
profile similar to that of other amphetamines43; this aspect has been 
confirmed in the literature23,32-35.  
A systematic review and meta-analysis evaluating the drug 
options for ADHD management concluded that there were no 
significant differences in the relative risk of adverse events between 
non-stimulants and short-acting or extended-release stimulants44. 
The tolerability and safety of LDX were investigated in a 4-week 
study including 290 children33. The most common adverse events 
in children were loss of appetite, dizziness, dry mouth, irritability, 
insomnia, upper abdominal pain, nausea, vomiting and weight loss 
(Table 1). Most of the events were reported mainly in the first week, 
with a reduction over the 4 weeks of treatment tested, and the most 
frequent ones were loss of appetite (39% vs. 4% for placebo) and 
insomnia (19% vs. 3%)33. Although a study with small samples 
has suggested differences in the prevalence of adverse events that 
occur with the use of LDX when used in treatment-naïve patients 
in comparison with previously treated patients, the symptom profile 
was identical45. 
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Table 1. Summary of adverse events occurring in > 5% of children 
in any group after treatment with lisdexamfetamine dimesylate 
(30, 50 or 70 mg) in short and long-term studies33,44 – indicates 
no reported data
Adverse event Occurrence (%)
Short-term 
treatment 
(n = 218)33
Long-term 
treatment 
(n = 272)34
Decreased appetite 39.0 33
Insomnia 18.8 17
Headache 11.9 18
Upper abdominal pain 11.9 11
Irritability 9.6 10
Vomiting 8.7 9
Nasopharyngitis 5.0 10
Weight loss 9.2 18
Nausea 6.0 -
Dizziness 5.0 -
Dry mouth 4.6 -
Cough 1.4 7
Long-term safety
Results from a long-term treatment study showed that, after 11 
months of treatment, adverse events occurring in more than 10% 
of patients included decreased appetite, headache, weight decrease, 
insomnia, upper abdominal pain and upper respiratory tract 
infection. Of all treatment-emergent adverse events, 97.5% were 
considered to be of mild or moderate severity34. Long-term use of 
amphetamines has been associated with a temporary delay in growth 
rates in pediatric patients, something that appears to be significantly 
associated with weight loss. In a multicenter, open-label study with 
272 children who received LDX 30-70 mg/day for 12 months, 
patients showed a significant increase in height (3.8 cm), while there 
was no difference in weight (a non-significant mean gain of 272 g 
compared with baseline values) during the observation period34. 
When normalized for age and gender, compared with baseline, 
the mean change in percentile was -13.4 over 12 months (baseline 
percentile: 60.6; 12 months percentile: 47.2)34. Consistent with other 
psychostimulants, after treatment with LDX there was a slowing in 
growth rate measured by weight gain in comparison with children of 
the same age and gender34. The results from a non-controlled study 
of 281 children 6-13 years of age with ADHD receiving LDX for 
up to 15 months showed that LDX was associated with significant 
reductions in height and weight16. Compared with age-appropriate 
standards, children who were given LDX had reduced gains in 
height and weight16. The authors noted that more studies are required 
to determine the effect of LDX on final stature in adulthood and 
recommend that, as with other psychostimulants, weight and height 
should be monitored27,46, and treatment discontinuation should be 
considered in children who show inadequate growth and weight gain. 
Cardiovascular risk
Based on data for amphetamines in general, cardiovascular risk 
associated with the use of LDX is believed to be low and changes 
in blood pressure (BP) and heart rate (HR) are considered to be 
small and not clinically significant47. In a Phase III study of 290 
children, no significant change was observed in electrocardiogram 
(ECG) parameters or blood pressure33. However, LDX treatment was 
associated with significant increases in heart rate relative to placebo, 
with the largest increase (4-5 bpm) observed with the highest dose of 
LDX (70 mg)33. An evaluation of cardiovascular parameters in 420 
adult patients (18-55 years of age) with ADHD given doses of 30, 50 
and 70 mg/day of LDX for 4 weeks showed no significant changes in 
ECG and blood pressure48. There was, however, a significant increase 
in heart rate and pulse for LDX (2.8, 4.2 and 5.2 bpm for 30, 50 
and 70 mg doses, respectively, compared with 0.0 for placebo), but 
the severity was considered to be mild to moderate and of minimal 
clinical concern48. 
The use of amphetamines may be associated with changes in 
ECG parameters, although those changes have not been shown 
to be of clinical significance45. There was previous concern about 
cardiovascular risk associated with the use of methylphenidate 
and amphetamines in the treatment of ADHD in children49, but 
evidence indicates that cardiovascular events are rare (and frequently 
associated with a pre-existing pathology) and there is no increase 
in the risk of sudden death45,47. The frequency of sudden death with 
the use of stimulants has been estimated to be around 0.56 deaths 
per 1 million prescriptions50, which is considered to be lower than 
that of the general public45. Despite there being no reports of cases 
of sudden death associated with the use of LDX in the literature, 
the probability of sudden death occurring must be considered to be 
similar to that of other psychostimulant medications51. 
Potential for abuse
Psychostimulants as a group have a potential for abuse which must 
be taken into consideration by the physician. There have been reports 
of non-medical use by healthy individuals to increase cognitive 
performance and, in particular, academic performance52-54. One 
possible advantage of LDX is the absence of clinically significant 
psychoactive effects when administered by intranasal or intravenous 
means, in addition to the absence of an accelerated effect (in 
terms of Cmax or Tmax) when used by intranasal means
32, potentially 
reducing the probability of abuse and misuse55. In addition, since 
LDX is an inactive prodrug, it is believed that the slow release of 
d-amphetamine (produced by hydrolysis of LDX) produces a slow, 
steady therapeutic effect, potentially avoiding the large/fast increases 
in dopamine that are associated with the reinforcing effects of drug 
abuse56. 
The abuse potential of LDX is considered to be less than that 
of d-amphetamine. In a study of potential abuse comparing both 
treatments in adult stimulant abusers, LDX 50 mg administered 
intravenously did not result in significant abuse-related craving 
scores (P = 0.290) when compared with placebo19. The results 
indicated that after 50 mg doses of LDX and 20 mg doses of 
d-amphetamine administered intravenously, only d-amphetamine 
differed significantly from the placebo in drug-craving ratings19. In 
a placebo-controlled study, orally-administered LDX (50, 100 and 
150 mg) was compared with d-amphetamine 40 mg (equivalent to 
100 mg of LDX) in adults (18-55 years of age) with a history of 
stimulant abuse22. Of the doses tested, only d-amphetamine and LDX 
at the highest dose (150 mg) differed significantly from placebo in 
craving scores on the Drug Rating Questionnaire-Subject (DRQS) 
scale. In a pair-wise comparison of equivalent doses, d-amphetamine 
(40 mg) was associated with significantly higher craving scores 
compared with LDX (50 or 100 mg), indicating that abuse liability 
(“drug craving”) is attenuated with LDX22. There are no studies 
available on the abuse potential of LDX compared with other 
controlled-release stimulants used in the treatment of ADHD, and 
there are as yet no data available for populations other than adults.
Discussion
LDX is an inactive prodrug that is metabolized to the active 
fraction (d-amphetamine) through rate-limited hydrolysis, resulting 
in the steady release of d-amphetamine and a prolonged effect 
following a single daily dose. In controlled clinical studies, LDX 
proved to be effective for the treatment of ADHD in children and 
adolescents, with results comparable to those of other available 
psychostimulants. The therapeutic effects of LDX are achieved 
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less than 1.5 hours after administration and are maintained for up 
to 13 hours. In addition, LDX is effective in long-term maintenance 
therapy. The safety and tolerability profile of LDX is similar to that 
observed with other psychostimulants. The pharmacokinetic profile 
of LDX is associated with a lower abuse potential than immediate-
release psychostimulants.
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